Thompson et al. report clinical outcomes and immunological correlates of a phase 1 trial of a peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma.
- Eric M. Thompson
- David M. Ashley
- Daniel Landi